Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Q3 2021 Blueprint Medicines Corp Earnings Call Transcript

Oct 28, 2021 / 12:30PM GMT
Release Date Price: $113.33 (+8.75%)
Operator

Good morning. My name is Maxine, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines 3Q 2021 Financial Results Conference Call. (Operator Instructions)

Kristin Hodous of Blueprint Medicines, you may begin your conference.

Kristin Hodous
Blueprint Medicines Corporation - Senior Manager of IR

Good morning, everyone, and welcome to Blueprint Medicines Third Quarter 2021 Financial and Operating Results Conference Call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

Today, on our call, Jeff Albers, our Chief Executive Officer, will discuss Blueprint Medicines' third quarter 2021 business highlights; Christy Rossi, our Chief Commercial Officer, will provide a commercial update; Fouad Namouni, President

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot